Cargando…

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of serial data on CA 125, the problem of interpreting a change over time is still unsolved. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuxen, M K, Sölétormos, G, Dombernowsky, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363637/ https://www.ncbi.nlm.nih.gov/pubmed/11355938 http://dx.doi.org/10.1054/bjoc.2001.1787

Ejemplares similares

Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period
por: Abu Hassan, Suher O, et al.
Publicado: (2017)

Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
por: Menon, U, et al.
Publicado: (1999)

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
por: Peters-Engl, C, et al.
Publicado: (1999)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer
por: Zhao, Dan, et al.
Publicado: (2018)

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
por: Gronlund, B, et al.
Publicado: (2004)

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
por: Canney, P. A., et al.
Publicado: (1984)

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
por: Kristiansen, Søren, et al.
Publicado: (2015)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer
por: Lee, Maria, et al.
Publicado: (2016)

Lung tumour markers in oncology practice: a study of TPA and CA125
por: Buccheri, G, et al.
Publicado: (2002)

Serum Tumor Marker Carbohydrate Antigen 125 Levels and Carotid Atherosclerosis in Patients with Coronary Artery Disease
por: Sang, Guo-Yao, et al.
Publicado: (2018)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer
por: Cook, A M, et al.
Publicado: (2000)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

The effect of CA125 on metastasis of ovarian cancer: old marker new function
por: Yuan, Qin, et al.
Publicado: (2017)

Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy
por: Bernal-Bello, David, et al.
Publicado: (2022)

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
por: Hawkins, R. E., et al.
Publicado: (1989)

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.
por: Fisken, J., et al.
Publicado: (1993)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Prognostic value of serum CA-125 in patients with advanced epithelial ovarian cancer followed by complete remission after adjuvant chemotherapy
por: Moon, Jong Ho, et al.
Publicado: (2013)

Exploring the Glycosylation of Serum CA125
por: Saldova, Radka, et al.
Publicado: (2013)

Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
por: Zhang, Hui, et al.
Publicado: (2015)

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
por: Sánchez Vega, Juan Fernando, et al.
Publicado: (2018)

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma
por: Bagherlou, Nazanin, et al.
Publicado: (2020)

Reply: Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy
por: Chen, Wei-Chun, et al.
Publicado: (2022)

CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels
por: Wang, Yi-Sheng, et al.
Publicado: (2021)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

THE ROLE OF SALIVARY AND SERUM CA125 AND ROUTINE BLOOD TESTS IN PATIENTS WITH OVARIAN MALIGNANCIES
por: Vuković, Ante, et al.
Publicado: (2021)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression
por: Lassen, U N, et al.
Publicado: (1999)

Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients
por: Hickey, K P, et al.
Publicado: (1999)

Frequency of serum tumour marker monitoring.
por: Colls, B. M.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_ala076l5rvvu3p5nj8q3sqfc95